Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation.
暂无分享，去创建一个
O. Toupance | Y. Lebranchu | B. Hurault de Ligny | Y. Le Meur | I. Étienne | F. Bridoux | S. Caillard | P. Le Pogamp | J. Marliere | A. Al Najjar | C. Mousson
[1] S. D. Filippo,et al. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. , 2005 .
[2] S. Gruber,et al. Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients , 2005, Transplantation.
[3] L. Rostaing,et al. Sequential Protocols using Basiliximab versus Anti-Thymocyte Globulins in Renal-Transplant Patients Receiving Mycophenolate Mofetil and Steroids , 2004, Transplantation.
[4] O. Toupance,et al. Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF‐containing Triple Therapy , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.